A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) (NCT04710576)
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham - Children's of Alabama — Birmingham, Alabama
Age range: 2 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (121 Sites)
Showing the first 25 of 121 sites.
- University of Alabama at Birmingham - Children's of Alabama — Birmingham, Alabama
- University of Alabama at Birmingham — Birmingham, Alabama
- City of Hope — Duarte, California
- University of Southern California Norris Comprehensive Cancer Center — Los Angeles, California
- University of California, Los Angeles (UCLA) - Medical Center — Los Angeles, California
- Stanford Cancer Center — Stanford, California
- Children's National Medical Center — Washington D.C., District of Columbia
- University of Florida (UF) — Gainesville, Florida
- Mayo Clinic - Jacksonville — Jacksonville, Florida
- University of Miami — Miami, Florida
- AdventHealth Orlando — Orlando, Florida
- Moffitt — Tampa, Florida
- Emory University — Atlanta, Georgia
- Northside Hospital — Atlanta, Georgia
- The University of Chicago Medical Center (UCMC) — Chicago, Illinois
- Indiana University Health Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
- Franciscan Health Indianapolis — Indianapolis, Indiana
- Tulane University Medical Center — New Orleans, Louisiana
- Johns Hopkins Kimmel Cancer Center — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- University of Massachusetts Memorial Medical Center — Worcester, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
- Henry Ford Hospital — Detroit, Michigan
📞 Contact the Study Coordinator
Phone: (781) 419-1400
Email: clinicaltrials@syndax.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Graft-versus-host-disease
- A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease — Phoenix, Arizona
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) — Duarte, California
- A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease — Birmingham, Alabama
Explore by condition: All Chronic Graft-versus-host-disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.